Note I - Equity-based Compensation - Stock Options, SARs and RSUs Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016 USD ($) $ / shares shares
Outstanding (in shares)	3,457
Outstanding (in dollars per share) | $ / shares	$ 5.61
RSUs granted (in shares)	3
Options / SARs / RSUs cancelled/forfeited/expired (in shares)	(98)
Options / SARs / RSUs cancelled/forfeited/expired (in dollars per share) | $ / shares	$ 7.29
Options / SARs exercised and RSUs vested (in shares)	(647)
Options / SARs exercised and RSUs vested (in dollars per share) | $ / shares	$ 6.34
Outstanding (in shares)	2,713	[1]
Outstanding (in dollars per share) | $ / shares	$ 5.38	[1]
Outstanding	3 years 73 days	[1],[2]
Outstanding | $	$ 18,341	[1],[3]
Exercisable at September 30, 2016 (2) (in shares)	1,642	[4]
Exercisable at September 30, 2016 (2) (in dollars per share) | $ / shares	$ 7.75	[4]
Exercisable at September 30, 2016 (2)	2 years 313 days	[2],[4]
Exercisable at September 30, 2016 (2) | $	$ 7,327	[3],[4]

[1] Due to the ceiling imposed on the SAR grants, the outstanding amount above can be exercised for a maximum of 2,410 shares of the Company’s common stock as of September 30, 2016. SAR grants made prior to January 1, 2009 are convertible for a maximum number of shares of the Company’s common stock equal to 50% of the SARs subject to the grant. SAR grants made on or after January 1, 2009 and before January 1, 2010 are convertible for a maximum number of shares of the Company’s common stock equal to 75% of the SARs subject to the grant. SAR grants made on or after January 1, 2010 and before January 1, 2012 are convertible for a maximum number of shares of the Company’s common stock equal to 66.67% of the SARs subject to the grant. SAR grants made on or after January 1, 2012 are convertible for a maximum number of shares of the Company’s common stock equal to 50% of the SARs subject to the grant.

[2] Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have indefinite contractual term.

[3] Calculation of aggregate intrinsic value is based on the share price of the Company’s common stock on September 30, 2016 ($12.01 per share).

[4] Due to the ceiling imposed on the SAR grants, the exercisable amount above can be exercised for a maximum of 1,339 shares of the Company’s common stock as of September 30, 2016.